Sartorius AG - Company Profile
Powered by 
All the sales intelligence you need on Sartorius AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sartorius AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sartorius AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sartorius AG (Sartorius) is a medical device company that offers laboratory and process technology equipment. The company's product portfolio includes cell lines; cell culture media; reagents; bioreactors; technologies for the separation, purification, and concentration of biological intermediates and end products; solutions for storage and transportation; lab water systems; laboratory balances; pipettes; and consumables, such as filters and microbiological test kits; among others. It also offers services such as bioprocess consulting and engineering, biologics testing, cell culture media services, instrument service, and validation services. Sartorius serves pharmaceutical and biotechnology companies, academic research facilities, and quality control labs in the chemical and food industries. The company’s production facilities are located in the UK, Belgium, Switzerland, Tunisia, India, the US, China, Israel, and Slovenia. Sartorius is headquartered in Gottingen, Niedersachsen, Germany.
Headquarters
Germany
Address
Otto-Brenner-Str. 20, Goettingen, Niedersachsen, 37079
Website
www.sartorius.com
Telephone
49 551 3080
No of Employees
12,627
Industry
Medical Equipment
Ticker Symbol & Exchange
SRT (ETR)
Revenue (2024)
$4.0B
4.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
84.5%
(2024 vs 2023)
Market Cap*
$18.4B
Net Profit Margin (2024)
XYZ
76.6%
(2024 vs 2023)
* As of and is in US$
Sartorius AG premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Biolayer Interferometry (BLI) Systems: | Bioprocess Consulting & Engineering | Ambr |
| Octet R2 BLI System | Cell Culture Media Services | Octet |
| Octet R4 BLI System | Biologics Testing | Flexsafe |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In March, the company introduced its Eveo Cell Therapy Platform. |
| 2026 | Corporate Changes/Expansions | In May, the company opened a new competence center for cell and gene therapy components in Freiburg, Germany. |
| 2025 | Corporate Changes/Expansions | In September, the company expanded its Sartorius Stedim Biotech in Illkirch, near Strasbourg, France. |
Competitor Comparison
| Key Parameters | Sartorius AG | Thermo Fisher Scientific Inc | Danaher Corp | Merck KGaA | Becton Dickinson and Co |
|---|---|---|---|---|---|
| Headquarters | Germany | United States of America | United States of America | Germany | United States of America |
| City | Goettingen | Waltham | Washington | Darmstadt | Franklin Lakes |
| State/Province | Niedersachsen | Massachusetts | WashingtonD.C. | Hessen | New Jersey |
| No. of Employees | 12,627 | 125,000 | 58,000 | 62,136 | 72,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lothar Kappich | Chairman | Executive Board | 2007 | 69 |
| Michael Grosse | Chief Executive Officer | Senior Management | 2025 | 59 |
| Florian Funck | Chief Financial Officer | Senior Management | 2024 | 55 |
| Dietmar Muller | Vice Chairman | Executive Board | 2025 | 50 |
| Rene Faber | Head - Bioprocess Solutions Division | Senior Management | 2019 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer